pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›FOUNDAYO
drug · small molecule
save

FOUNDAYO

updated 6mo ago
by $LLY ELI LILLY & Co🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 7
  • drugorforglipron calcium8 co-mentions · 2 sources
  • tagSmall Molecule4 co-mentions · 2 sources
  • tagApproval4 co-mentions · 1 sources
  • companyEli Lilly and Co2 co-mentions · 1 sources
  • drugOzempic2 co-mentions · 1 sources
  • drugWegovy2 co-mentions · 1 sources
  • drugWegovy Pill2 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Unknown (across all indications), with 3 investigational indications.

all catalysts(0)

nothing on the calendar yet

News(10)

  • Blackstone bets $1.5B on Pfizer’s obesity drug
    The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.
    biopharma_dive · 4d ago
  • Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
    Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about th…
    biospace · 5d ago
  • FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
    Twelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.
    biospace · 7d ago
  • Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3
    If approved, the oral GLP-1 would be Eli Lilly’s second marketed drug for obstructive sleep apnea after the GIP/GLP-1 injectable Zepbound secured the first approval in the space in December 2024.
    biospace · 7d ago
  • STAT+: Heart association meeting’s readout is trending ‘neutral’
    The theme of the American Heart Association meetings was "neutral" results. Yet no one wants to stop pursuing inflammation or Lp(a) lowering.
    stat · 7d ago
  • STAT+: Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies
    Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in two late-stage studies, but it doesn’t appear as effective as Lilly’s injectable drug Zepbound.
    stat · 7d ago
  • Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
    The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.
    biopharma_dive · 10d ago
  • This week in charts: 3 drug launches Wall Street is watching
    The latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of medicines highlighted in quarterly earnings this week.
    biopharma_dive · 10d ago
  • Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
    The drug’s third-quarter sales numbers came in well above consensus estimates, widening Novo’s early edge over Eli Lilly in the latest battleground for weight loss medicines.
    biopharma_dive · 12d ago
  • Novo, Lilly battle for oral GLP-1 dominance with data tit for tat
    Novo CEO Mike Maziar Doustdar insists that his company is ahead of fierce rival Eli Lilly as oral Wegovy rises to 8 million total prescriptions since its January launch.
    biospace · 12d ago
view all news mentions →
brand
FOUNDAYO
generic
ORFORGLIPRON CALCIUM
MOA
12.1 Mechanism of Action FOUNDAYO is a GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor. GLP-1 is a physiological regulator of appetite and caloric intake. GLP-1 receptors are present in brain regions that regulate appetite. In animal studies, orforglipron distributed to and activated neurons in brain regions that regulate appetite and food intake.
indication
1 INDICATIONS AND USAGE FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended.
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 37m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?